Press release
Ankylosing spondylitis Drugs Market 2034: EMA, PDMA, FDA Approvals, NDA Approval, Clinical Trials, Medication, Prevalence, Incidence, Therapies, and Companies by DelveInsight
Ankylosing spondylitis Drugs Market
(Albany, USA) DelveInsight's "Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Ankylosing spondylitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics.
The Ankylosing spondylitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Ankylosing spondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ankylosing spondylitis Market Forecast [https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key facts of the Ankylosing spondylitis Market Report:
* The Ankylosing spondylitis market size was valued at USD 4200 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In November 2023, UCB announced new long-term data from the BIMZELX (bimekizumab) Phase IIb study BE AGILE and its open-label extension (OLE). Patients with ankylosing spondylitis (AS) treated with bimekizumab, an IL-17A and IL-17F inhibitor, demonstrated sustained improvements in signs and symptoms, disease activity, physical function, and health-related quality of life for up to five years, maintaining a consistent safety profile throughout the treatment period. These findings were presented at the American College of Rheumatology (ACR) Convergence 2023.
* In 2023, the total prevalent population of ankylosing spondylitis in the 7MM region was approximately 2,300,000, with the highest number of cases observed in the United States.
* In the 7MM, approximately 1,130,000 cases of diagnosed ankylosing spondylitis were reported in 2023. According to the analysis, these cases are projected to increase by 2034 with a moderate compound annual growth rate (CAGR).
* In 2023, the United States reported the highest number of age-specific prevalent cases, with approximately 270,000 cases among individuals aged 40-59 years, followed by those under 40 years of age.
* In 2023, Italy had the highest number of diagnosed prevalent cases of ankylosing spondylitis in the EU4 region, totaling approximately 192,000 cases.
* Key Ankylosing spondylitis Companies: Galapagos NV, Affibody Therapeutic/Inmagene Biopharmaceuticals, Sunshine Guojian Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Akeso, Biocad, Tasly Pharmaceutical, Hanyang University Seoul Hospital, UCB Biopharma SRL, AbbVie, Eli Lilly and Company, and others
* Key Ankylosing spondylitis Therapies: JYSELECA (filgotinib), ABY-035 (izokibep), 608 Dose A, Jaktinib, AK111, BCD-085, Jitongning tablets, Golimumab, Bimekizumab, Upadacitinib, Ixekizumab, and others
* The Ankylosing spondylitis epidemiology based on gender analyzed that Ankylosing spondylitis is more common in males than females
Ankylosing spondylitis Overview
Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and reduced mobility. Ankylosing spondylitis is classified as a type of axial spondyloarthritis and is strongly associated with the HLA-B27 genetic marker. Ankylosing spondylitis symptoms often begin in early adulthood, with lower back pain that worsens over time and improves with physical activity.
Ankylosing spondylitis progression can lead to fusion of the vertebrae, causing spinal rigidity and postural changes. Ankylosing spondylitis can also affect other areas, such as the eyes (uveitis), heart, and lungs. Ankylosing spondylitis diagnosis involves clinical evaluation, imaging tests like X-rays or MRI, and genetic testing for HLA-B27.
Ankylosing spondylitis treatment aims to manage symptoms and slow disease progression. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for Ankylosing spondylitis, while biologics like TNF inhibitors and IL-17 inhibitors are used for severe cases. Ankylosing spondylitis management also includes physical therapy and exercise to maintain mobility.
Ankylosing spondylitis research continues to explore new therapeutic approaches, with ongoing clinical trials for novel biologics and small-molecule inhibitors. Ankylosing spondylitis awareness and early intervention are crucial for improving patient outcomes.
Get a Free sample for the Ankylosing spondylitis Market Report - https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Ankylosing spondylitis Market
The dynamics of the Ankylosing spondylitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Ankylosing spondylitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Ankylosing spondylitis Epidemiology Segmentation:
The Ankylosing spondylitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Prevalent cases of Ankylosing Spondylitis in the 7MM
* Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
* Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in 7MM
* Treated cases of Ankylosing Spondylitis in the 7MM
* Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
* Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
Download the report to understand which factors are driving Ankylosing spondylitis epidemiology trends @ Ankylosing spondylitis Epidemiological Insights [https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Ankylosing spondylitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ankylosing spondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Ankylosing spondylitis Therapies and Key Companies
* JYSELECA (filgotinib): Galapagos NV
* ABY-035 (izokibep): Affibody Therapeutic/Inmagene Biopharmaceuticals
* 608 Dose A: Sunshine Guojian Pharmaceutical
* Jaktinib: Suzhou Zelgen Biopharmaceuticals
* AK111: Akeso
* BCD-085: Biocad
* Jitongning tablets: Tasly Pharmaceutical
* Golimumab: Hanyang University Seoul Hospital
* Bimekizumab: UCB Biopharma SRL
* Upadacitinib: AbbVie
* Ixekizumab: Eli Lilly and Company
Request for sample report @ Ankylosing Spondylitis Clinical Trials [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Ankylosing spondylitis Market Strengths
* Certain initiatives have been taken by private and government organizations to raise awareness about the disease. The Spondylitis Association of America (SAA) began officially celebrating SpA Awareness Month in May.
* There has been an increase in pharmaceutical companies' investment in the research and development of drugs.
Ankylosing spondylitis Market Opportunities
* Several pharmaceutical key players have taken the initiative to meet the unmet needs of the Ankylosing Spondylitis market's present situation.
* The prevalence of Ankylosing Spondylitis diagnosis codes more than doubled between 2006 and 2016; increase in prevalence creates a lucrative opportunity for the Ankylosing Spondylitis market.
Scope of the Ankylosing spondylitis Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Ankylosing spondylitis Companies: Sunshine Guojian Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Akeso, Biocad, Tasly Pharmaceutical, Hanyang University Seoul Hospital, UCB Biopharma SRL, AbbVie, Eli Lilly and Company, and others
* Key Ankylosing spondylitis Therapies: JYSELECA (filgotinib), ABY-035 (izokibep), 608 Dose A, Jaktinib, AK111, BCD-085, Jitongning tablets, Golimumab, Bimekizumab, Upadacitinib, Ixekizumab, and others
* Ankylosing spondylitis Therapeutic Assessment: Ankylosing spondylitis current marketed and Ankylosing spondylitis emerging therapies
* Ankylosing spondylitis Market Dynamics: Ankylosing spondylitis market drivers and Ankylosing spondylitis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Ankylosing spondylitis Unmet Needs, KOL's views, Analyst's views, Ankylosing spondylitis Market Access and Reimbursement
Discover more about therapies set to grab major Ankylosing spondylitis market share @ Ankylosing spondylitis Treatment Landscape [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Ankylosing spondylitis Market Report Introduction
2. Executive Summary for Ankylosing spondylitis
3. SWOT analysis of Ankylosing spondylitis
4. Ankylosing spondylitis Patient Share (%) Overview at a Glance
5. Ankylosing spondylitis Market Overview at a Glance
6. Ankylosing spondylitis Disease Background and Overview
7. Ankylosing spondylitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ankylosing spondylitis
9. Ankylosing spondylitis Current Treatment and Medical Practices
10. Ankylosing spondylitis Unmet Needs
11. Ankylosing spondylitis Emerging Therapies
12. Ankylosing spondylitis Market Outlook
13. Country-Wise Ankylosing spondylitis Market Analysis (2020-2034)
14. Ankylosing spondylitis Market Access and Reimbursement of Therapies
15. Ankylosing spondylitis Market Drivers
16. Ankylosing spondylitis Market Barriers
17. Ankylosing spondylitis Appendix
18. Ankylosing spondylitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ankylosing-spondylitis-drugs-market-2034-ema-pdma-fda-approvals-nda-approval-clinical-trials-medication-prevalence-incidence-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ankylosing spondylitis Drugs Market 2034: EMA, PDMA, FDA Approvals, NDA Approval, Clinical Trials, Medication, Prevalence, Incidence, Therapies, and Companies by DelveInsight here
News-ID: 3874267 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Ankylosing
Ankylosing Spondylitis Medication Market Size And Global Industry Forecast 2034
"As of 2024, the global ankylosing spondylitis (AS) medication market is valued at approximately $5 billion, driven by an increasing prevalence of the condition and a growing awareness of treatment options. The market is projected to reach roughly $9 billion by 2034, reflecting a robust growth trajectory over the next decade. The anticipated Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at around…
Ankylosing Spondylitis Market Surges With The Growing Geriatric Population World …
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Ankylosing Spondylitis Market Size and Its Estimated Growth Rate?
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
Ankylosing Spondylitis Uncovered: Market Dynamics and Future Projections
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/2638
Introduction:
The global ankylosing spondylitis market has been on a steady rise, reflecting the growing awareness and prevalence of this inflammatory condition. With a remarkable market size of $5,140.94 million in 2020, the projections indicate a substantial leap to $8,110.59 million by 2030. Ankylosing spondylitis, often misunderstood, is a complex disorder that affects the spine's flexibility and posture, potentially leading to severe complications if not managed effectively.
Unveiling Ankylosing…
Ankylosing Spondylitis Treatment Market to Witness Astonishing Growth by 2029
This Ankylosing Spondylitis Treatment Market research report focuses more on a number of distinctive as well as foremost market sectors. It further focuses market segmentation. Industry-specific interviews are carried out with market players to foresee future business growth. Various facets of the industry are also depicted here under each industry sector. Future development visions and a wide range of subjects are covered in this Ankylosing Spondylitis Treatment Market study report.…
Ankylosing Spondylitis Market Overview With Detailed Analysis 2022-2028
According to Precision Business Insights (PBI), the latest report, ankylosing spondylitis market is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/ankylosing-spondylitis-market/
Retail Pharmacy to Dominate the…
Ankylosing Spondylitis Market Challenges and Investment Opportunities by 2027
Allied Market Research published a report, titled, “Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast 2020–2027.” According to the report, the global Ankylosing Spondylitis industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027.
Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10631
Major players analyzed include AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen…
